FDA REGULATION OF DIGITAL HEALTH
|
|
- Angelica Dina Patrick
- 6 years ago
- Views:
Transcription
1 FDA REGULATION OF DIGITAL HEALTH DIGITAL HEALTH LEGAL AND REGULATORY BOOTCAMP WHAT YOU DON T KNOW YOU DON T KNOW
2 Table of Contents DIGITAL DIGITAL HEALTH LEGAL AND HEALTH REGULATORY LEGAL BOOTCAMP AND WHAT REGULATORY YO DON T KNOW YOU DON T KNOW BOOTCAMP WHAT YOU DON T KNOW YOU DON T KNOW PART 1 REGULATORY STRATEGY SECTION 1.1: SECTION 1.2: SECTION 1.3: SECTION 1.4: Overview of US FDA Regulatory Framework for Medical Devices Regulatory Pathways Post-Market Considerations New Developments & International Considerations PART 2 PRODUCT DEVELOPMENT CONSIDERATIONS SECTION 2.1: SECTION 2.2: SECTION 2.3: SECTION 2.4: Frequently Forgotten Best Practices Quality Management Systems Design & Development Verification & Validation Q&A
3 DIGITAL HEALTH LEGAL AND REGULATORY BOOTCAMP WHAT YOU DON T KNOW YOU DON T KNOW Part 1: Regulatory Strategy
4 1.1 Overview of US FDA Medical Device Regulation Risk & Novelty Class III Pacemaker/Defibrillator, Neurostimulators, Artificial Pancreas, Computer-Aided Diagnostic/Therapy Class II Cardiac Monitors, Peripheral Nerve Stimulators, Blood Glucose Meters, Imaging Diagnostic Software Class I Medical Device Data Systems, Wheelchair, Surgical Instruments, Orthotics, Liquid Bandages Regulatory Oversight REGULATORY OVERSIGHT General Controls Special Controls Performance Standards REGULATORY PATHWAYS Registration & Listing Pre-market Notification 510(k) Clearance De Novo Request Pre-market Approval (PMA) Prohibition against adulterated or misbranded devices Premarket notification 510(k) requirements Good Manufacturing Practices (GMPs) Labeling Registration of manufacturing facilities Listing of device types Record keeping Repair, replacement or refund
5 1.1 Medical Device Regulations Part Covers 11 Electronic Records and Signatures 50 Protection of Human Subjects 1 54 Financial Disclosures by Clinical Investigators 56 Institutional Review Boards 801 Product Labeling 803 Medical Device Reporting 806 Removals and Corrections 807 Registrations & Listings 812 Investigations Device Exemptions 814 Premarket Approvals (PMAs) (for class III devices) 820 Quality System Regulations (includes design controls) 822 Post-market Surveillance 860 Medical Device Classifications All medical device manufacturers must comply with all of the regulations, above 1 Greyed regulations are specific to clinical trials
6 Part 820 Defines the Requirements for: Management Responsibility (820.20); Quality Audits (820.22); Personnel training and qualification (820.25); Design Control (820.30); Control of documentation (820.40); Purchasing control (820.50); Product identification and traceability at all stages of production (820.60); Controlling and defining production and process (820.70); Defining and controlling inspection, measuring and test equipment (820.72); Product acceptance ( & ); Controlling nonconforming product (820.90); Instituting corrective action and preventive action (CAPA) ( ); Labeling and packaging controls ( & ); Handling, storage, distribution and installation ( , 150, 160 & 170); Control of records ( , 181, 184, 186 & 198); Servicing ( ); Statistical techniques ( ) Validating processes (820.75);
7 1.1 Overview Medical Device Regulation Recognized Standards Guidance In addition to the general set of medical device regulations, each device type has a specific regulation that describes the device and establishes the device's classification: Example: Infusion Pumps are governed by regulation 21 CFR Regulation establishes infusion pumps as class II devices
8 1.2 Regulatory Pathways Digital Health products fall within all device classes depending on intended use Intended use is determined by objective evidence Written or oral statements Device functionality Target market Requirements are defined in statutes, regulations, guidance, and standards
9 1.2 Regulatory Pathways Stage-Gate Process for the Development of Medical Devices Jan B. Pietzsch, Lauren A. Shluzas, M. Elisabeth Paté-Cornell, Paul G. Yock and John H. Linehan.J. Med. Devices 3(2), (Jun 17, 2009)
10 1.3 Post-Market Considerations Post-Approval Studies May be required as part of PMA or De Novo Reclassification May become increasingly important for machine learning algorithms that adapt post-launch Marketing & Advertising Must be truthful and non-misleading Must not result in intended use creep Post-Market Surveillance Must be prepared to maintain the QMS Must be prepared to handle complaints and MDR reporting FDA Inspections Must expect an FDA inspection 2-3 years after first product launch
11 1.3 Post-Market Considerations FDA Cybersecurity Expectations Impossible to completely mitigate risks through premarket controls alone Cybersecurity Risk Management Emphasize addressing vulnerabilities in a timely fashion Critical components include: Monitoring cybersecurity information sources Maintaining robust software lifecycle processes Understanding, assessing, and detecting presence and impact of a vulnerability or incident Establishing and communicating processes for vulnerability intake and incident handling Deploying methods to analyze, detect, and assess threat sources Using threat modeling to clearly define how to maintain safety and essential performance Adopting a coordinated vulnerability disclosure policy and practice Deploying mitigations that address cybersecurity risk early and prior to exploitation
12 1.4 Developments & Considerations REGULATION OF MEDICAL AND CERTAIN DECISIONS SUPPORT SOFTWARE. The term device, as defined in section 201(h), shall not include a software function that is intended: Administrative support of a health care facility Maintaining or encouraging a healthy lifestyle Serve as electronic patient records Transferring, storing, converting formats, or displaying clinical laboratory test or other device data and results Unless the function is intended to acquire, process, or analyze a medical image or a signal from an in vitro diagnostic device or a pattern or signal from a signal acquisition system, for the purpose of: Displaying, analyzing, or printing medical information about a patient, Supporting or providing recommendations to a health care professional, and Enabling such health care professional to independently review the basis for such recommendations. Section 3060 of the 21st Century Cures Act (Public Law )
13 1.4 Developments & Considerations FDA s Pre-Cert Program A voluntary program to develop a tailored approach to regulating by focusing primarily on the digital health technology developers rather than the product Goal is to establish a system to evaluate culture of quality and organizational excellence to allow software iterations in a timely fashion Participants include Apple, Fitbit, Samsung, Verily, J&J, and Roche Look for some form of program in place by end of Use of Real-World Evidence RWE may be suitable to support (or supplement the total evidence required for) the clearance or approval of a new device Real-World Data (RWD) are data relating to patient health status and/or the delivery of health care routinely collected from a variety of sources. Real-World Evidence (RWE) is the clinical evidence regarding the usage, and potential benefits or risks, of a medical product derived from analysis of RWD.
14 1.4 Developments & Considerations FDA is seeking public feedback on this version of the working model by May 31, 2018 at
15 1.4 Developments & Considerations
16 1.4 Developments & Considerations FDA Guidance Implementation of 21 st Century Cures 3060 Changes the definition of a medical device for certain software. Updates across multiple existing guidance documents. MDDS, EHR, and certain CDS are formally no longer under the definition of a medical device. Clinical Decision Support (CDS) Software Outlines how FDA intends to regulate CDS software. Introduces concept of PDS. The vast majority of comments include: Request for additional examples (many ask for more explanation with existing examples) Criteria for or change the requirement for understandable and publicly available and generally accepted clinical practice information regarding what is used by the software and as part of transparency determination. The guidance fails to take a risk-based approach and that intended use is not central to the decision process of regulated vs not. A large number of comments include: Machine learning and artificial intelligence are not considered at all in the document. Unclear how to address multifunctional software (e.g., software with modules where some are regulated and some are not). The guidance goes beyond what is outlined in Cures, though there is general agreement that introducing PDS is a good thing. That the guidance is overly restrictive and does not follow least-burdensome approach.
17 1.4 Developments & Considerations EU Medical Device Regulation New regulations for medical devices (including software) come into full force in 2020 Changes from MDD to MDR include: New pre-market scrutiny mechanism for high-risk devices Strengthening of post-market surveillance requirements Establishment of a comprehensive EU UDI database Increase focus and enforcement of clinical evidence requirements ISO 13485: 2016 Quality Management System Ability to obtain 3rd Party Certification Supports international marketing plans Can help achieve, but does not guarantee, compliance with FDA quality system regulations FDA considering recognizing the 2016 revision.
18 Part 2: Product Development Considerations DIGITAL HEALTH LEGAL AND REGULATORY BOOTCAMP WHAT YOU DON T KNOW YOU DON T KNOW
19 2.1 Frequently Forgotten Best Practices 1. Quality Starts with a Quality Management System Early establishment of a QMS and compliance with QMS policies & procedures are critical 2. Carefully Research, Define, and Document Requirements What are the operator requirements? Safety requirements? Patient requirements? Requirements driven by user needs 3. Consider Hazards/Risks and Incorporate into Requirements Functionalities that prevent or mitigate known hazards should be added to the list of requirements and tested appropriately 4. Establish and Follow Change Control Procedures Changes to design require careful consideration and approval from a broad group of stakeholders 5. Traceability is Crucial The ability to trace from requirements through risk management to testing output, while maintaining change control, is critical.
20 2.1 Frequently Forgotten Best Practices 6. Maintain a Revision History Retrospectively re-constructing the software revision history is difficult and painful Maintain a revision history that describes changes and reason(s) for making them 7. Adequately Define and Document V&V Activities Test cases including acceptance criteria, results, and pass/fail disposition must always be documented (i.e., If it isn t documented, it didn t happen! ) Testing prior to plan approval is forbidden and will result in re-testing 8. Consider Future Versions of the Device and Associated Functionalities If possible, write code in a modular fashion to reduce V&V burden for additional functionalities and/or claims extensions Regulatory clearance/approval for new functionality/claims will only require a simple license to implement the functionality on units already on the market
21 2.2 Quality Management System Quality Management System Manufacturers must establish and follow policies and processes for relevant aspects of the QMS Design Controls, Document Controls, Process Controls, and CAPA are common FDA audit observations Management are subject to personal civil and criminal liability for violations under the Park doctrine
22 2.2 Design Control General (a) Design & Development Planning (b) Design Input (c) Design Transfer (h) Design Verification (f) Design Validation (g) Design Changes (i) Design Review (e) Design History File (DHF) (j)
23 2.3 Design & Development Design Concept Tech Development Plan (SW Quality Assurance Plan) Technology Specification (SW Req. Spec.) Technology Development Process General Overview Risk Management Plan (Hazard Analysis/Fault Tree) Development (SW Coding) Design V&V Product Release
24 2.3 Design & Development How FDA approaches Design Records: 1. Product description and intended use Product requirements 2. Traceability Matrix 3. Risk management file Mechanical Design Specifications Mechanical verification Intended use Intended users Intended use environment Product Requirements Electrical Design Specifications Electrical verification System Design Verification System Design Validation Summative Usability Business requirements Software Design Specifications Unit Verification Integration Verification Formative Usability Testing Risk management
25 2.3 Product Requirement Example
26 2.3 Product Requirement Example
27 2.3 Product Requirement Example
28 2.3 Design Specification Example
29 2.3 Design Specification Example
30 2.3 Risk Estimation & Evaluation Item # Hazard Type Potential Failure Mode Description Potential Harm Severity Potential Cause of Failure (Trigger Event) Occurrence Risk Risk Control Measure(s) Post- Mitigation Occ Risk Hazards Related to the Use of the Device HA 01 Results Error Erroneous results (high or low) Intervention to move user result in the wrong direction Ambient light causes user to misread display HA 02 Results Error Erroneous results (high or low) Intervention to move user result in the wrong direction Bias in recovered memory value HA 03 Results Error Result not produced Confused user, Customer irritation Result misidentified as control solution, therefore different coefficients will be used. Value not available for calculation or trending. Due to the use of the different coefficients, the result produced will be biased when compared to the result produced if the sample had been appropriately identified.
31 2.3 Verification & Validation Definitions Verification = confirmation by examination and provision of objective evidence that specified requirements have been fulfilled Validation = establishing by objective evidence that device specifications conform with user needs and intended use(s) Verification & Validation Models Static vs. Dynamic Analysis (i.e., product/process reviews vs. beta testing) Product Audits V&V Task Iteration Test Planning & Design What will be tested? How? What are the acceptance criteria?
32 2.3 Verification & Validation Code Reviews, Inspection, Module Testing, Integration Testing Formal or Informal System or Functional Design Reviews Documenting and reviewing test results is critical
33 2.4 Verification Protocol Example
34 2.4 Verification Protocol Example
35 2.4 Unit & Integration Output
36 2.4 Verification Output
37 2.4 Trace Matrix Examples
38 2.4 Trace Matrix Examples
39 2.4 Usability Why is it important?
40 2.4 Usability Definitions Formative Usability Evaluation Assessing, at one or more stages during the device development process, a user interface or user interactions with the user interface to identify the interface s strengths and weaknesses and to identify potential use errors that would or could result in harm to the patient or user. Human-Factors Validation (aka Summative Usability) Testing conducted at the end of the device development process to assess user interactions with a device user interface to identify use errors that would or could result in serious harm to the patient or user. Human factors validation testing is also used to assess the effectiveness of risk management measures. Human factors validation testing represents one portion of design validation.
41 2.4 Summative Usability Examples
42 2.4 How it fits together Mechanical Design Specifications Mechanical verification Intended use Intended users Intended use environment Product Requirements Electrical Design Specifications Electrical verification System Design Verification System Design Validation Summative Usability Business requirements Software Design Specifications Unit Verification Integration Verification Formative Usability Testing Risk management
43 Contact Information DIGITAL DIGITAL HEALTH LEGAL AND HEALTH REGULATORY LEGAL BOOTCAMP AND WHAT REGULATORY YO DON T KNOW YOU DON T KNOW BOOTCAMP WHAT YOU DON T KNOW YOU DON T KNOW FDA Regulatory Expert Over 30 years of experience in the medical device, health information technology, and invitro diagnostics ( IVD ) industries. SCOTT THIEL, MT(ASCP), MBA, RAC Director, Navigant scott.thiel@navigant.com
Combination Products Verification, Validation & Human Factors Sept. 12, 2017
Combination Products Verification, Validation & Human Factors Sept. 12, 2017 Speaker Scott Thiel Director, Navigant Consulting Regulatory consulting in Life Sciences industry with focus on medical devices,
More informationCOMMUNICATION FROM THE COMMISSION TO THE EUROPEAN PARLIAMENT. pursuant to Article 294(6) of the Treaty on the Functioning of the European Union
EUROPEAN COMMISSION Brussels, 9.3.2017 COM(2017) 129 final 2012/0266 (COD) COMMUNICATION FROM THE COMMISSION TO THE EUROPEAN PARLIAMENT pursuant to Article 294(6) of the Treaty on the Functioning of the
More informationSoftware as a Medical Device (SaMD)
Software as a Medical Device () Working Group Status Application of Clinical Evaluation Working Group Chair: Bakul Patel Center for Devices and Radiological Health US Food and Drug Administration NWIE
More informationRecast de la législation européenne et impact sur l organisation hospitalière
Recast de la législation européenne et impact sur l organisation hospitalière MEDICAL DEVICES IN BELGIUM. What s up? Brussels44Center 24.10.2017 Valérie Nys Need for changes? Regulatory system is highly
More informationGuidance for Industry and FDA Staff Use of Symbols on Labels and in Labeling of In Vitro Diagnostic Devices Intended for Professional Use
Guidance for Industry and FDA Staff Use of Symbols on Labels and in Labeling of In Vitro Diagnostic Devices Intended for Professional Use Document issued on: November 30, 2004 The draft of this document
More informationPreparing for the new Regulations for healthcare providers
Preparing for the new Regulations for healthcare providers Cathal Brennan, Medical Device Assessor HPRA Information Day on Medical Devices 23 rd October 2014 Brussels, 26.9.2012 COM(2012) 542 final 2012/0266
More informationImportance of ICH Guidance in Fulfilling Process Validation Requirements
Importance of ICH Guidance in Fulfilling Process Validation Requirements Presented by: Gamal Amer All rights reserved. Do not copy without permission. Principal 1 Premier Compliance Services, Inc. Process
More informationHow to survive the MDR
How to survive the MDR Louis Habets LifetecZONe, 21 September 2017 1 Agenda About the Medical Device Regulation Specific project! Highlights only showing where to find Discussion and Questions LifetecZONe,
More informationWhat We Heard Report Inspection Modernization: The Case for Change Consultation from June 1 to July 31, 2012
What We Heard Report Inspection Modernization: The Case for Change Consultation from June 1 to July 31, 2012 What We Heard Report: The Case for Change 1 Report of What We Heard: The Case for Change Consultation
More informationCENTER FOR DEVICES AND RADIOLOGICAL HEALTH. Notice to Industry Letters
CENTER FOR DEVICES AND RADIOLOGICAL HEALTH Standard Operating Procedure for Notice to Industry Letters PURPOSE This document describes the Center for Devices and Radiological Health s (CDRH s, or Center
More informationFinal Document. Title: The GHTF Regulatory Model. Authoring Group: Ad Hoc GHTF SC Regulatory Model Working Group
GHTF/AHWG-GRM/N1R13:2011 Final Document Title: The GHTF Regulatory Model Authoring Group: Ad Hoc GHTF SC Regulatory Model Working Group Endorsed by: The Global Harmonization Task Force Date: 13 April 2011
More informationAccreditation & Designation of NB
Accreditation & Designation of NB Bert Roossien Medical Devices Notified Body BSI Netherlands 07 June 2018 Copyright 2018 BSI. All rights reserved MDF1200 (EU) No 920/2013 In particular, they shall not
More informationBuilding Quality into Medical Device Documentation and Impact of New Device Regulation (Context: Inhaled Drug Devices) v4
Building Quality into Medical Device Documentation and Impact of New Device Regulation (Context: Inhaled Drug Devices) v4 Paul Brooks SVP Healthcare Solutions Representing BSI Notified Body EU Medical
More informationThe Medical Device Regulation: Transitioning between old and new
Association of British Healthcare Industries The Medical Device Regulation: Transitioning between old and new www.abhi.org.uk www.bdia.org.uk Introduction In May 2017, the new Medical Device Regulation
More informationOphthalmic Digital Health Areas
FDA Perspectives on Ophthalmic Mobile Medical Applications and Telemedicine Ronald Schuchard Center for Devices and Radiological Health Office of Device Evaluation Ophthalmic Digital Health Areas Software
More informationCAMD Transition Sub Group FAQ IVDR Transitional provisions
Disclaimer: CAMD Transition Sub Group FAQ IVDR Transitional provisions The information presented in this document is for the purpose of general information only and is not intended to represent legal advice
More informationImplementing Quality Systems
Implementing Quality Systems CGMP By The Sea August 29, 2006 Chris Joneckis, Ph.D. Senior Advisor For CMC Issues Center For Biologics Evaluation And Research Add FDA Bar and Presentation Overview Driving
More informationMedical Devices cyber risks and threats
Medical Devices cyber risks and threats David Grainger Senior Medical Device Specialist MHRA The challenges of software medical device regulation. david.grainger@mhra.gov.uk Current framework 1998 In Vitro
More informationNational Coordinated Registry Network (CRN) Think-tank
National Coordinated Registry Network (CRN) Think-tank The Value of Real World Data for Innovation within FDA What can CRNs offer? Murray Sheldon, MD Associate Director for Technology and Innovation FDA/CDRH
More informationClaudio Pincus, President, The Quantic Group R. Owen Richards, President, Quantic Regulatory Services Daniel Pincus, Consultant, The Quantic Group
FDA Compliance and Regulatory Symposium Understanding the FDA s Latest cgmp Guidances: Opportunities and Pitfalls Claudio Pincus, President, The Group R. Owen Richards, President, Regulatory Services Daniel
More informationFiscal 2007 Environmental Technology Verification Pilot Program Implementation Guidelines
Fifth Edition Fiscal 2007 Environmental Technology Verification Pilot Program Implementation Guidelines April 2007 Ministry of the Environment, Japan First Edition: June 2003 Second Edition: May 2004 Third
More informationThe Biological Weapons Convention and dual use life science research
The Biological Weapons Convention and dual use life science research Prepared by the Biological Weapons Convention Implementation Support Unit I. Summary 1. As the winner of a global essay competition
More informationclarification to bring legal certainty to these issues have been voiced in various position papers and statements.
ESR Statement on the European Commission s proposal for a Regulation on the protection of individuals with regard to the processing of personal data on the free movement of such data (General Data Protection
More informationTGA Discussion Paper 3D Printing Technology in the Medical Device Field Australian Regulatory Considerations
TGA Discussion Paper 3D Printing Technology in the Medical Device Field Australian Regulatory Considerations MTAA Response - October 2017 October 2017 Australian Regulatory Considerations Page 1 of 7 Level
More informationProtection of Privacy Policy
Protection of Privacy Policy Policy No. CIMS 006 Version No. 1.0 City Clerk's Office An Information Management Policy Subject: Protection of Privacy Policy Keywords: Information management, privacy, breach,
More informationEN Official Journal of the European Union L 117/176 REGULATION (EU) 2017/746 OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL.
Seite 1 von 176 5.5.2017 EN Official Journal of the European Union L 117/176 REGULATION (EU) 2017/746 OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL of 5 April 2017 on in vitro diagnostic medical devices
More informationCDER s Office of Pharmaceutical Quality (OPQ): Delivering on the 21 st Century Quality Goals
CDER s Office of Pharmaceutical Quality (OPQ): Delivering on the 21 st Century Quality Goals Lawrence X. Yu, Ph.D. Director (acting) Office of Pharmaceutical Science Food and Drug Administration IFPAC
More informationNational Medical Device Evaluation System: CDRH s Vision, Challenges, and Needs
National Medical Device Evaluation System: CDRH s Vision, Challenges, and Needs Jeff Shuren Director, CDRH Food and Drug Administration Center for Devices and Radiological Health 1 We face a critical public
More informationThank you for the opportunity to comment on the Audit Review and Compliance Branch s (ARC) recent changes to its auditing procedures.
Jim Riva, Chief Audit Review and Compliance Branch Agricultural Marketing Service United States Department of Agriculture 100 Riverside Parkway, Suite 135 Fredericksburg, VA 22406 Comments sent to: ARCBranch@ams.usda.gov
More informationProf. Steven S. Saliterman. Department of Biomedical Engineering, University of Minnesota
Department of Biomedical Engineering, University of Minnesota http://saliterman.umn.edu/ 1) Device Discovery and Ideation 2) Medical Device Regulations 3) Product Life Cycle 4) Design Controls 5) Medical
More information4/8/2018. Prof. Steven S. Saliterman Department of Biomedical Engineering, University of Minnesota
Department of Biomedical Engineering, University of Minnesota http://saliterman.umn.edu/ 1) Device Discovery and Ideation 2) Medical Device Regulations 3) Product Life Cycle 4) Design Controls 5) Medical
More informationRulemaking Hearing Rules of the Tennessee Department of Health Bureau of Health Licensure and Regulation Division of Emergency Medical Services
Rulemaking Hearing Rules of the Tennessee Department of Health Bureau of Health Licensure and Regulation Division of Emergency Medical Services Chapter 1200-12-01 General Rules Amendments of Rules Subparagraph
More informationA Brief Introduction to the Regulatory Environment of Medical Device Supervision. CFDA Department of Legal Affairs Liu Pei
A Brief Introduction to the Regulatory Environment of Medical Device Supervision CFDA Department of Legal Affairs Liu Pei Development Trend of Medical Device Industry Development Opportunities of Medical
More informationITI Comment Submission to USTR Negotiating Objectives for a U.S.-Japan Trade Agreement
ITI Comment Submission to USTR-2018-0034 Negotiating Objectives for a U.S.-Japan Trade Agreement DECEMBER 3, 2018 Introduction The Information Technology Industry Council (ITI) welcomes the opportunity
More informationPROPOSED DOCUMENT. Global Harmonization Task Force. Title: Medical Devices: Post Market Surveillance: Content of Field Safety Notices
SG2(PD)/N57R6 PROPOSED DOCUMENT Global Harmonization Task Force Title: Medical Devices: Post Market Surveillance: Content of Field Safety Notices Authoring Group: Study Group 2 of the Global Harmonization
More informationEnvironmental Protection Agency
Good Laboratory Management: Means compliance with the correct regulations for each individual study.. Environmental Protection Agency Established 1970 To enforce environmental protection standards Clean
More informationMedical Device Risk Management
Page 1 of 14 X Medical Device Risk Management Posted 14 February 2018 By Darin OppenheimerSuraj Ramachandran This article focuses on risk management in the medical device industry and reviews organizational
More informationICH Q10 Pharmaceutical Quality System
Safeguarding public health ICH Q10 Pharmaceutical Quality System An EU Regulator s Perspective Presentation overview Why does Q10 exist and what were the desired outcomes Content of the Q10 step 2 document
More informationthe SPD company Dr Clive Simon, Principal, The SPD Company.
the SPD company With decades of local and international experience at the coalface, The SPD Company s specialists have built a solid repertoire of in-depth technical knowledge within the highly-regulated
More informationASSEMBLY - 35TH SESSION
A35-WP/52 28/6/04 ASSEMBLY - 35TH SESSION TECHNICAL COMMISSION Agenda Item 24: ICAO Global Aviation Safety Plan (GASP) Agenda Item 24.1: Protection of sources and free flow of safety information PROTECTION
More informationVice President, Regulatory Affairs, Clinical Research, and Quality Assurance AREAS OF EXPERTISE
Vice President, Regulatory Affairs, Clinical Research, and Quality Assurance AREAS OF EXPERTISE Medical Device Expert (21 years with FDA, 18 years in the device industry) Planning, implementing, and managing
More informationSHTG primary submission process
Meeting date: 24 April 2014 Agenda item: 8 Paper number: SHTG 14-16 Title: Purpose: SHTG primary submission process FOR INFORMATION Background The purpose of this paper is to update SHTG members on developments
More informationCouncil of the European Union Brussels, 8 March 2017 (OR. en)
Council of the European Union Brussels, 8 March 2017 (OR. en) Interinstitutional File: 2012/0267 (COD) 10729/4/16 REV 4 LEGISLATIVE ACTS AND OTHER INSTRUMTS Subject: PHARM 44 SAN 285 MI 479 COMPET 403
More informationExecutive Summary Industry s Responsibility in Promoting Responsible Development and Use:
Executive Summary Artificial Intelligence (AI) is a suite of technologies capable of learning, reasoning, adapting, and performing tasks in ways inspired by the human mind. With access to data and the
More informationFY 2008 (October 1, 2007 September 30, 2008) NIMS Compliance Objectives and Metrics for Local Governments
FY 2008 (October 1, 2007 September 30, 2008) NIMS Compliance Objectives and Metrics for Local Governments Introduction Homeland Security Presidential Directive (HSPD)- 5 Management of Domestic Incidents
More informationPiloting MDevSPICE - the Medical Device Software Process Assessment Framework
Piloting MDevSPICE - the Medical Device Software Process Assessment Framework Marion Lepmets Regulated Software Research Centre Dundalk Institute of Technology Dundalk, Ireland marion.lepmets@dkit.ie Fergal
More informationDeciding When to Submit a 510(k) for a Software Change to an Existing Device Draft Guidance for Industry and Food and Drug Administration Staff
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 Deciding When to Submit a 510(k) for a Software Change to an Existing Device Draft Guidance for Industry and Food
More informationIN VITRO DIAGNOSTICS: CAPITA EXOTICA
IN VITRO DIAGNOSTICS: CAPITA EXOTICA Axon IVD seminar 12 September 2012 Erik Vollebregt www.axonadvocaten.nl orphan subjects that will soon develop to full-blown issues Stand alone software Data protection
More informationA stronger system to protect the health and safety of Canadians. Exploring the Future of the Food Regulatory Framework Under the Food and Drugs Act
A stronger system to protect the health and safety of Canadians Exploring the Future of the Food Regulatory Framework Under the Food and Drugs Act Purpose and Scope To stimulate a discussion about how
More informationPrimary IVF Conditions for Registration For Assisted Reproductive Treatment Providers under the Assisted Reproductive Treatment Act 2008
Primary IVF Conditions for Registration For Assisted Reproductive Treatment Providers under the Assisted Reproductive Treatment Act 2008 Effective: 1 June 2018 Contents SECTION 1: Background... 3 SECTION
More informationWANT TO PARTICIPATE IN RESEARCH? THERE S AN APP FOR THAT!
WANT TO PARTICIPATE IN RESEARCH? THERE S AN APP FOR THAT! SECURITY AND PRIVACY ISSUES WITH THE INCREASED USE OF CONNECTED DEVICES, APPS, AND SOCIAL MEDIA IN RESEARCH. PRESENTED BY: DAVID MATA, SENIOR ASSOCIATE,
More informationSAUDI ARABIAN STANDARDS ORGANIZATION (SASO) TECHNICAL DIRECTIVE PART ONE: STANDARDIZATION AND RELATED ACTIVITIES GENERAL VOCABULARY
SAUDI ARABIAN STANDARDS ORGANIZATION (SASO) TECHNICAL DIRECTIVE PART ONE: STANDARDIZATION AND RELATED ACTIVITIES GENERAL VOCABULARY D8-19 7-2005 FOREWORD This Part of SASO s Technical Directives is Adopted
More informationFebruary 5, 2010 VIA ELECTRONIC SUBMISSION
February 5, 2010 VIA ELECTRONIC SUBMISSION Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers Lane, rm. 1061 Rockville, MD 20852 Re: Current Good Manufacturing Practice
More informationPrivacy Values and Privacy by Design Annie I. Antón
Privacy Values and Privacy by Design Annie I. Antón Silicon Flatirons The Technology of Privacy University of Colorado School of Law January 11, 2013 Online, how do we assure the public and what is
More informationTechnical Documentation - Key pit falls
Technical Documentation - Key pit falls Itoro Udofia, PhD Global Head, Orthopaedic & Dental Devices Presented by Ibim Tariah Ph.D Technical Director Healthcare Solutions September 2012 TFD00101ENUK Overview
More information2008 Course Programs Schedule
2008 Course Programs Schedule Basic Laboratory Safety Laboratory Safety Biostatistics for the Non-Statistician - Basic Applied cgmps for Pharmaceutical and Allied Industries Good Clinical Practices (GCP)
More informationEU regulatory system for robots
EU regulatory system for robots CE marking of robots today and in the future Felicia Stoica DG GROW Summary Access to the EU market - marking for robots EU safety laws for robots and role of EN standards
More informationWHO Regulatory Systems Strengthening Program
WHO Regulatory Systems Strengthening Program MVP RHT RSS CRS www.who.int Minimal capacity met Eligibility for vaccine PQ WHO listed NRAs WHO NRA 5 step capacity building Development of NRA benchmarking
More informationLeveraging Med Device Expertise to Develop Combination Products
Leveraging Med Device Expertise to Develop Combination Products 20 th Annual Drug Delivery Partnership Conference January 20, 2016 Dirk Smith VP of Technology Solutions Minnetronix, Inc. 250 employees,
More informationDraft executive summaries to target groups on industrial energy efficiency and material substitution in carbonintensive
Technology Executive Committee 29 August 2017 Fifteenth meeting Bonn, Germany, 12 15 September 2017 Draft executive summaries to target groups on industrial energy efficiency and material substitution
More informationWRHA Supply Chain New Technology Workshop Supply Chain Forum November 17, 2010
WRHA Supply Chain New Technology Workshop Supply Chain Forum November 17, 2010 Prepared & Presented by: Gwen Connon, Contract Specialist, WRHA Contracting Services Sarah Kelso, Manager, Clinical Engineering,
More informationMinistry of Justice: Call for Evidence on EU Data Protection Proposals
Ministry of Justice: Call for Evidence on EU Data Protection Proposals Response by the Wellcome Trust KEY POINTS It is essential that Article 83 and associated derogations are maintained as the Regulation
More informationSafety related product corrective action
Safety related product corrective action Brian Such Standards Solutions Project Manager British Standards Institution Copyright 2017 BSI. All rights reserved 1 03/07/2017 Safety related product corrective
More informationOSIsoft. Users Conference 2013
OSIsoft. Users Conference 2013 Pharmaceutical and Life Sciences: Towards a Recipe Driven Company and the Critical Role of the Real Time Infrastructure Continuous Process Verification By: Martin Browning,
More informationBUREAU OF LAND MANAGEMENT INFORMATION QUALITY GUIDELINES
BUREAU OF LAND MANAGEMENT INFORMATION QUALITY GUIDELINES Draft Guidelines for Ensuring and Maximizing the Quality, Objectivity, Utility, and Integrity of Information Disseminated by the Bureau of Land
More informationApplication for Assessment of a full quality assurance system regarding Measuring Instruments in accordance with MID
Application for Assessment of a full quality assurance system regarding Measuring Instruments in accordance with MID Company (applicant): hereby applies to RISE Research Institutes of Sweden AB, as Notified
More informationConnecting People, Science and Regulation
Connecting People, Science and Regulation Bethesda Towers 4350 East West Highway Suite 600 Bethesda, MD 20814 USA Tel: +1 (301) 656-5900 Fax: +1 (301) 986-0296 www.pda.org PDA Europe ggmbh Am Borsigturm
More informationOur position. ICDPPC declaration on ethics and data protection in artificial intelligence
ICDPPC declaration on ethics and data protection in artificial intelligence AmCham EU speaks for American companies committed to Europe on trade, investment and competitiveness issues. It aims to ensure
More informationGlobal Harmonization Task Force
Global Harmonization Task Force How to minimize risks without constraining innovation and harming free trade The role of international standards And their application at regional and national levels Cornelis
More information1 SERVICE DESCRIPTION
DNV GL management system ICP Product Certification ICP 4-6-3-5-CR Document number: ICP 4-6-3-5-CR Valid for: All in DNV GL Revision: 2 Date: 2017-05-05 Resp. unit/author: Torgny Segerstedt Reviewed by:
More informationDNVGL-CP-0338 Edition October 2015
CLASS PROGRAMME DNVGL-CP-0338 Edition October 2015 The electronic pdf version of this document, available free of charge from http://www.dnvgl.com, is the officially binding version. FOREWORD DNV GL class
More informationAn Essential Health and Biomedical R&D Treaty
An Essential Health and Biomedical R&D Treaty Submission by Health Action International Global, Initiative for Health & Equity in Society, Knowledge Ecology International, Médecins Sans Frontières, Third
More informationOfficial Journal of the European Union L 117. Legislation. Legislative acts. Volume May English edition. Contents REGULATIONS
Official Journal of the European Union L 117 English edition Legislation Volume 60 5 May 2017 Contents I Legislative acts REGULATIONS Regulation (EU) 2017/745 of the European Parliament and of the Council
More informationPrivacy Policy SOP-031
SOP-031 Version: 2.0 Effective Date: 18-Nov-2013 Table of Contents 1. DOCUMENT HISTORY...3 2. APPROVAL STATEMENT...3 3. PURPOSE...4 4. SCOPE...4 5. ABBREVIATIONS...5 6. PROCEDURES...5 6.1 COLLECTION OF
More informationBritish Columbia s Environmental Assessment Process
British Columbia s Environmental Assessment Process Seminar #2 Guide for Aboriginal Groups and the General Public on the BC Environmental Assessment Process February 23, 2016 Paul Craven About the BC Environmental
More informationINFCIRC/57. 72/Rev.6. under. Safetyy. read in. Convention. involve. National Reports. on Nuclear 2015.
Atoms for Peace and Development Information Circular INFCIRC/57 72/Rev.6 Date: 19 January 2018 General Distribution Original: English Guidelines regarding Convention National Reports under the on Nuclear
More informationTest, Validation and Regulatory Requirements for Medical Electronics
Test, Validation and Regulatory Requirements for Medical Electronics 1 Life Cycle Approach 2 Why Risk Risks and associated measures are called in the following regulations / standards: 43 sections in the
More informationCDRH PMA Critical to Quality (CtQ) Pilot
1 Informative series of workshops featuring emerging trends in medical technology regulatory science, MDIC projects and subject matter experts sharing perspectives, progress and opportunities. CDRH PMA
More informationType Approval JANUARY The electronic pdf version of this document found through is the officially binding version
STANDARD FOR CERTIFICATION No. 1.2 Type Approval JANUARY 2013 The electronic pdf version of this document found through http://www.dnv.com is the officially binding version The content of this service
More informationViolent Intent Modeling System
for the Violent Intent Modeling System April 25, 2008 Contact Point Dr. Jennifer O Connor Science Advisor, Human Factors Division Science and Technology Directorate Department of Homeland Security 202.254.6716
More informationFINAL DOCUMENT. Title: Medical Devices Post Market Surveillance: Content of Field Safety Notices. Endorsed by: The Global Harmonization Task Force
GHTF/SG2/N57R8:2006 FINAL DOCUMENT Title: Medical Devices Post Market Surveillance: Content of Field Safety Notices Authoring Group: Study Group 2 Endorsed by: The Global Harmonization Task Force Date:
More informationCDRH INNOVATION INITIATIVE. February 2011 Center for Devices and Radiological Health U.S. Food and Drug Administration
CDRH INNOVATION INITIATIVE February 2011 Center for Devices and Radiological Health U.S. Food and Drug Administration 1 Table of Contents EXECUTIVE SUMMARY... 3 BACKGROUND... 4 Innovation and Medical Device
More information4.1. Accurate: The information is a true reflection of the original observation.
SOP #: DOC-101 Page: 1 of 7 Effective Date: 1. POLICY STATEMENT: The Principal Investigator and research team members are required to prepare and maintain adequate and accurate case histories designed
More informationEN Official Journal of the European Union L 117/1 REGULATION (EU) 2017/745 OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL.
Seite 1 von 200 5.5.2017 EN Official Journal of the European Union L 117/1 REGULATION (EU) 2017/745 OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL of 5 April 2017 on medical devices, amending Directive
More informationNEMA XR X-ray Equipment for Interventional Procedures User Quality Control Mode
NEMA XR 27-2012 X-ray Equipment for Interventional Procedures User Quality Control Mode Published by: National Electrical Manufacturers Association 1300 North 17th Street, Suite 1752 Rosslyn, Virginia
More informationUse of the Graded Approach in Regulation
Use of the Graded Approach in Regulation New Major Facilities Licensing Division Directorate of Regulatory Improvement and Major Projects Management Background Information for Meeting of the Office for
More informationPublic Information and Disclosure RD/GD-99.3
Public Information and Disclosure RD/GD-99.3 March, 2012 Public Information and Disclosure Regulatory Document RD/GD-99.3 Minister of Public Works and Government Services Canada 2012 Catalogue number CC172-82/2012E-PDF
More informationCAR Part IX Regulations for srpas Manufacturers. Presented by RPAS TF Eng to Industry, Jan. 24, 2019
CAR Part IX Regulations for srpas Manufacturers Presented by RPAS TF Eng to Industry, Jan. 24, 2019 Overview Regulatory responsibilities for srpas manufacturers; CAR Standard 922 Grandfathering TCCA processes
More informationEXPLORATION DEVELOPMENT OPERATION CLOSURE
i ABOUT THE INFOGRAPHIC THE MINERAL DEVELOPMENT CYCLE This is an interactive infographic that highlights key findings regarding risks and opportunities for building public confidence through the mineral
More informationThe EFPIA Perspective on the GDPR. Brendan Barnes, EFPIA 2 nd Nordic Real World Data Conference , Helsinki
The EFPIA Perspective on the GDPR Brendan Barnes, EFPIA 2 nd Nordic Real World Data Conference 26-27.9.2017, Helsinki 1 Key Benefits of Health Data Improved decision-making Patient self-management CPD
More informationJ. Lawrence Stevens, RAC 833 E. Rosedale Dr. East Alton, IL (office) (mobile)
J. Lawrence Stevens, RAC 833 E. Rosedale Dr. East Alton, IL 62024 314-499-5148 (office) 714-473-0863 (mobile) Larry@fdadeviceexpert.com INTRODUCTION: Over 20 years of FDA experience encompassing virtually
More informationMedical Technology Association of NZ. Proposed European Union/New Zealand Free Trade Agreement. Submission to Ministry of Foreign Affairs & Trade
Medical Technology Association of NZ Proposed European Union/New Zealand Free Trade Agreement Submission to Ministry of Foreign Affairs & Trade February 2016 1 Introduction The Medical Technology Association
More informationDiana Gordick, Ph.D. 150 E Ponce de Leon, Suite 350 Decatur, GA Health Insurance Portability and Accountability Act (HIPAA)
Diana Gordick, Ph.D. 150 E Ponce de Leon, Suite 350 Decatur, GA 30030 Health Insurance Portability and Accountability Act (HIPAA) NOTICE OF PRIVACY PRACTICES I. COMMITMENT TO YOUR PRIVACY: DIANA GORDICK,
More informationResponsible Data Use Assessment for Public Realm Sensing Pilot with Numina. Overview of the Pilot:
Responsible Data Use Assessment for Public Realm Sensing Pilot with Numina Overview of the Pilot: Sidewalk Labs vision for people-centred mobility - safer and more efficient public spaces - requires a
More informationIVD REGULATION IN THE EU. CE Mark your IVDs in compliance with the European IVD Regulation
IVD REGULATION IN THE EU CE Mark your IVDs in compliance with the European IVD Regulation 1 Agenda Regulatory background and definition of an IVD Product Classification & Conformity Assessment Routes Product
More informationHuman Factors Points to Consider for IDE Devices
U.S. FOOD AND DRUG ADMINISTRATION CENTER FOR DEVICES AND RADIOLOGICAL HEALTH Office of Health and Industry Programs Division of Device User Programs and Systems Analysis 1350 Piccard Drive, HFZ-230 Rockville,
More informationJanuary 8, Licensing Requirements for Implantable Medical Devices Manufactured by 3D Printing; Draft Guidance. Dear Sir or Madame:
701 Pennsylvania Avenue, NW Suite 800 Washington, D.C. 20004 2654 Tel: 202 783 8700 Fax: 202 783 8750 www.advamed.org January 8, 2019 Bureau of Policy, Science and International Programs Therapeutic Products
More informationHuman Factors: Unknowns, Knowns and the Forgotten
Human Factors: Unknowns, Knowns and the Forgotten Peter C. Burns Standards Research & Development, Motor Vehicle Safety Transport Canada 2018 SIP-adus Workshop: Human Factors 1 Outline Examples of bad
More informationJustin McCarthy John Amoore, Paul Blackett, Fran Hegarty, Richard Scott. Regulations, Guidance and Standards
Justin McCarthy John Amoore, Paul Blackett, Fran Hegarty, Richard Scott Regulations, Guidance and Standards 1 What s it all about? Clarity regarding the difference between: Regulations Guidance Standards
More informationProf. Steven S. Saliterman. Department of Biomedical Engineering, University of Minnesota
Department of Biomedical Engineering, University of Minnesota http://saliterman.umn.edu/ ISO 14971 Risk Management as Part of Design Control Human Factors and Usability Engineering Definitions How People
More information